The researchers concluded in their abstract, “This first clinical study to target eIF4E in human malignancy demonstrates clinical activity and associated molecular responses in leukemic blasts.”
She states, "We also found that ribavirin not only blocks eIF4E, it has no side effect on patients." [EurekAlert]
Dr. Assouline adds, "We had striking clinical improvements with even partial and complete remissions.” [EurekAlert]
Dr. Borden concludes, "Combination therapy with chemotherapeutic agents may enhance the efficacy of this treatment. Trials in the near future are planned to overcome this and we are looking forward to more complete remissions." [EurekAlert]
"We also hope to test whether ribavirin is as effective in the treatment of other cancers with dysregulated eIF4E. Our laboratory studies suggest this is likely." [EurekAlert]
2013 is well underway and Australian companies need to know whether they should invest in IT skills training or pay a premium for the people they need.
If you want to know which choices are being made in your sector, what skills are hard to find, which sectors intend to hire or fire and where the IT spend is going, this free report is must have.
William Atkins completed educational degrees in science (bachelor’s in physics and mathematics) from Illinois State University (Normal, United States) and business (master’s in entrepreneurship and bachelor’s in industrial relations) from Western Illinois University
